 |
|
|
| |
Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo
|
| |
| |
EASL 2025 May 7-10 Amsterdam
Mary E. Rinella1, Manal F. Abdelmalek2, Elisabetta Bugianesi3, Anna M.G. Calí4, Laurent Castera5,6, Kristiane A. Engebretsen4, Jacob George7, Wah Kheong Chan8, Niels Krarup4, Michelle T. Long4, Philip N. Newsome9,10, Cláudia P. Oliveira11, Georgios Papatheodoridis12, Ahsan Shoeb4, Salvatore Petta13, Michael Roden14-16, Arun J. Sanyal17, Yusuf Yilmaz18, Vlad Ratziu19, on behalf of the ESSENCE study group
AASLD2024: Phase 3 ESSENCE trial: Semaglutide in metabolic dysfunction-associated steatohepatitis
|
| |
|
|
|
|
|
